• Accueil >
  • Publications >
  • Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

1 déc. 2015BMC Cancer

DOI : 10.1186/s12885-015-1257-2

Auteurs

Nadine Houédé, Philippe Beuzeboc, Sophie Gourgou, Diego Tosi, Laura Moise, Gwenaëlle Gravis, Remy Delva, Aude Fléchon, Igor Latorzeff, Jean-Marc Ferrero, Stéphane Oudard, Sophie Tartas, Brigitte Laguerre, Delphine Topart, Guilhem Roubaud, Hanane Agherbi, Xavier Rebillard, David Azria